Feng Xu

HER kinase inhibition in patients with HER2- and HER3-mutant cancers

David M. Hyman, Sarina A. Piha‐Paul, Helen Won et al. · Nature · 2018 · 783 citations

Medicine, Cancer Biology, Oncology +14

Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer

J.-Y. Douillard, Salvatore Siena, J Cassidy et al. · Annals of Oncology · 2014 · 604 citations · Full text

Medicine, Oncology, Pharmacotherapy +9

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 589 citations

Medicine, Oncology, Pharmacology +15

Skin Toxicity Evaluation Protocol With Panitumumab (STEPP), a Phase II, Open-Label, Randomized Trial Evaluating the Impact of a Pre-Emptive Skin Treatment Regimen on Skin Toxicities and Quality of Life in Patients With Metastatic Colorectal Cancer

Mario E. Lacouture, Edith P. Mitchell, Bilal Piperdi et al. · Journal of Clinical Oncology · 2010 · 475 citations

Medicine, Oncology, Pharmacology +16

Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer

Ahmad Awada, Rámón Colomer, Kenichi Inoue et al. · JAMA Oncology · 2016 · 313 citations · Full text

Medicine, Oncology, Pharmacology +17